Voice-preserving Treatment of Larynegeal Papilloma

喉乳头状瘤的保声治疗

• 批准号: 7086799
• 负责人: ZHI WANG
• 金额: $ 24.29万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7086799
• 关键词: angiogenesis inhibitors; chemoprevention; clinical research; combination therapy; human subject; human therapy evaluation; larynx neoplasms; laser therapy; neoplasm /cancer blood supply; neoplasm /cancer relapse /recurrence; nonsteroidal antiinflammatory agent; oxidoreductase inhibitor; patient oriented research; postoperative state; voice

DESCRIPTION (provided by applicant): Respiratory recurrent papilloma (RRP) is the most common benign tumor occurring in children. This disease usually involves the vocal cords or other regions of the larynx, thereby, resulting in a poor voice. Surgical removal is the current management for RRP, but it is a very traumatic procedure. The surgery often produces vocal cord scarring and leads to permanent voice dysfunction. Our previous studies have shown the efficacy and safety of a microvascular targeting technique (MVT) for RRP treatment using the 585 nm pulsed dye laser (PDL). This technique provides a less traumatic alternative to surgery. However, postoperative recurrence of lesions still remains a problem because of microvascular regrowth. This study is a continuation of our effort to develop a new and less traumatic treatment for RRP. In this study, we will develop a new, combined RRP treatment with PDL and Celecoxib. We will determine if Celecoxib, a newly developed inhibitor of cyclooxygenase (COX)-2, can provide a long-term inhibitory effect on RRP through its anti-angiogenic activity and the synergic effect produced with the laser therapy. The hypothesis is that postoperative administration of Celecoxib will provide a long-term inhibitory effect on microvascular regrowth and on COX-2 enzyme, thereby, preventing RRP from recurring after the PDL therapy. Our specific aim in this study is to determine the synergic effect between PDL and Celecoxib and long-term efficacy of Celecoxib in preventing postoperative RRP recurrence. We will compare this new combined strategy with traditional CO2 laser treatment in 30 adult patients. This is the first time to combined this new laser MVT technique with a COX-2 inhibitor for microvascular targeting therapy of RRP. This combined strategy, if successful in this proposed study, will provide a new and ideal "voice-preserving" therapy for RRP that will deliver long-term efficacy in managing RRP and will be safe and convenient enough for use in out-patient treatment.

描述（由申请人提供）：呼吸道复发性乳头状瘤（RRP）是儿童最常见的良性肿瘤。这种疾病通常涉及声带或喉部的其他区域，从而导致声音变差。手术切除是目前治疗RRP的方法，但这是一个非常创伤性的过程。手术经常会产生声带疤痕，并导致永久性的声音功能障碍。我们之前的研究已经显示了使用585 nm脉冲染料激光（PDL）进行RRP治疗的微血管靶向技术（MVT）的有效性和安全性。这种技术提供了一种创伤较小的手术替代方案。然而，由于微血管再生，术后病变复发仍然是一个问题。这项研究是我们努力开发一种新的、创伤性较小的RRP治疗方法的延续。在这项研究中，我们将开发一种新的，结合PDL和塞来昔布的RRP治疗。我们将确定塞来昔布，一种新开发的环氧合酶（考克斯）-2抑制剂，是否可以通过其抗血管生成活性和与激光治疗产生的协同作用对RRP提供长期抑制作用。假设塞来昔布术后给药将对微血管再生和考克斯-2酶产生长期抑制作用，从而防止PDL治疗后RRP复发。本研究的具体目的是确定PDL和塞来昔布之间的协同作用以及塞来昔布预防术后RRP复发的长期疗效。我们将在30例成人患者中比较这种新的联合策略与传统的CO2激光治疗。这是首次将这种新的激光MVT技术与考克斯-2抑制剂结合用于RRP的微血管靶向治疗。如果在这项拟议的研究中取得成功，这种联合策略将为RRP提供一种新的理想的"声音保留"疗法，该疗法将在管理RRP方面提供长期疗效，并且在门诊治疗中使用足够安全和方便。